Audit: QRS - Humanin for Health & Longevity

Audit conducted on 06/08/2026 03:48 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	91
Passed	82
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Verified across all populated variables. Spot checks: time_2_sub vs ER l.462; time_3_sub vs ER l.417; action_3 vs ER l.407; marker why-columns vs ER table l.492-504.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Cautious ER phrasing preserved, e.g. ‘None validated’, ‘Unknown’, ‘Allometric human conversion is not validated’ (ER l.400, l.407, l.462).
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindication thresholds and absolutes carried across unchanged (eGFR < 30, < 5 y remission, curative-intent chemo/radiotherapy).
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications and Key Interactions both drawn from ER Key Interactions & Contraindications; benefits/risks from their own ER sections; monitoring from ER Monitoring Protocol & Defining Success.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	All named agents (somatropin, tesamorelin, CJC-1295, ipamorelin, sermorelin, glargine, glipizide, glyburide, repaglinide, metformin, semaglutide, tirzepatide, empagliflozin, berberine, alpha-lipoic acid, cinnamon, Gymnema sylvestre, MOTS-c, SS-31, dasatinib, quercetin, fisetin, cyclophosphamide, cisplatin) appear in the ER for the same facts. No PMIDs, NCT IDs or expert names appear.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind appear in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s measured, evidence-weighted register.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Expert and data-driven while remaining readable; the unresolved protective-signal vs strain-marker tension is carried through.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Presents the evidence state; no directives.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Monitoring targets and cadence are presented as the ER presents them, not as instructions to a patient.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No ‘recommend’, ‘advise’, or ‘should’ constructions in the QRS voice.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person address anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms used are those the ER itself uses and that the sheet’s reference function requires; no gratuitous jargon.
2.8	Information is presented in a concise and very compact manner	🟢	Every field is a compressed phrase or single clause.
2.9	It DOES NOT address the reader directly	🟢	No second-person address anywhere in the document.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Content assumes a proactive, risk-aware reader (sourcing verification, batch testing, cancer-screening gate).
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Cadence and monitoring panel presuppose willingness to run an effortful protocol.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Framing is not general-population; it addresses an intervention with no human data and an unregulated supply chain.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Risk weighting foregrounds tumor promotion and absent human safety data, which is the decisive signal for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The term ‘anti-aging’ does not appear.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Formal terminology used throughout (‘injection’, ‘malignancy’, ‘induration’, ‘erythema’).

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, gate headings, tier labels and Monitoring column headers are present verbatim (l.445, 490, 538, 569, 588, 619, 650, 654-656, 825).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All data-qrs-var spans named by the checklist are present: page_title, header_topic, header_subline_date, header_subline_model, at_a_glance, action_1-3*, time_1-3, benefits_, stop_items, caution_items, risks_, marker_1-13_, monitoring_cadence, qualitative_item_1-6.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Non-checklist spans (website=”evidence_review”, website=”audit”, website=”full_review”) are left untouched (l.423, 426, 439).

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section is empty; the only unpopulated benefit tier (High) is governed by item 12.5, which explicitly forbids empty-state phrasing.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Qualitative Assessment bold labels are verbatim from the ER bullets (ER l.508-513 vs QRS l.829-859).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Monitoring row labels are verbatim ER biomarker names; qualitative labels verbatim.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji indicators anywhere; the ER’s tier emoji and the Conflicted markers are stripped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Content is held to the per-section budget; every field is a compressed phrase and no section is expanded beyond template capacity.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	HTML comment opens at l.2, immediately after <!doctype html> at l.1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening — at l.3, closing — at l.13, comment closes l.14.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; not rendered and not surfaced elsewhere.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values trimmed; only ‘duration’ is quoted, correctly, because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	l.4: er_filename: humanin_2026-0806-0002_Opus_ER.md
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	l.5: qrs_prompt_version: 26.7.02, matching QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	l.6: qrs_creation_date: 2026-0806-0257
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	l.7: qrs_creator_ai_nickname: Opus
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	‘Opus’ is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	l.8: qrs_creator_ai_fullname: Opus 5
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	‘Opus 5’ is nickname plus version number, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	l.9: qrs_filename: humanin_2026-0806-0002_Opus_QRS.html
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values trimmed; quoting used only where YAML requires it.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	l.22: ‘Humanin for Health & Longevity - Quick Reference Sheet’, matching the ER canonical_topic with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	l.417: ‘Humanin for Health & Longevity’.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	l.421: 08/06/2026, correct MM/DD/YYYY rendering of qrs_creation_date 2026-0806-0257.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	l.425: ‘Opus 5’.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header carries only the title and the template subline; no badge, AKA line, version stamp or audit date.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses the ER Conclusion (l.539-543): mechanism, the protective/strain tension, absent human dosing, unregulated supply.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	‘energy compartments’ (ER l.37), ‘keeping stressed cells alive’/’tumor cells as readily as healthy ones’ (ER l.539), ‘family longevity and slower loss of thinking ability’ (ER l.539), ‘worse survival in the oldest’ (ER l.539), ‘No trial has given it to a person’ (ER l.541), ‘supply is unregulated’ (ER l.543).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; ‘mitochondria’ rendered as ‘the cell’s energy compartments’.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years or sample sizes; the single reference is the unnamed ‘one study’.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No effect sizes, relative risks or statistics.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All six items trace to the ER Key Interactions & Contraindications section (l.349, 367-372).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All seven ER contraindication facts are represented across six items, with the cytotoxic-chemotherapy absolute contraindication merged into the chemo/radiotherapy item.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Six <li> elements inside the [stop_items] span (l.572-583).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Each item is a bare fact; the ER’s mechanistic rationale and parenthetical definitions are stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Qualifiers preserved: ‘< 5 y’, ‘BRCA1/2, Lynch’, ‘curative-intent’, ‘eGFR < 30 mL/min/1.73 m²’, ‘before growth completion’.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER Key Interactions & Contraindications section uses no ranking notation inside parentheses.
8.7	If no [stop_items] are present the section is left empty	N/A	[stop_items] are present (6 items).

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items trace to ER l.351-363.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All eight ER interaction bullets are represented except cytotoxic chemotherapy, which is correctly carried in Contraindications instead.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Seven <li> elements inside the [caution_items] span (l.591-609).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Each item is a bare agent-class label with its example list; severity wording and mitigating actions are stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists preserved and trimmed rather than dropped (e.g. glucose-lowering supplements shortened from six to four named agents).
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER Key Interactions & Contraindications section uses no ranking notation inside parentheses.
9.7	If no [caution_items] are present the section is left empty	N/A	[caution_items] are present (7 items).

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three action sets trace to the ER Therapeutic Protocol section (l.400, 407, 411).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Covers the three decisive implementation facts: absence of any validated human protocol, route, and the only long-term preclinical dosing reference.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct actionable implementation aspects are present; all three [action] sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine action fields carry ER-derived content; none is placeholder text.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Covers absence of a human time-to-effect signal (ER l.462), the 10-month body-composition readout (ER l.462), and the acute exercise window (ER l.417).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered from the absent human signal, to the Medium-tier body-composition benefit, to the acute endogenous-elevation lever.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time-to-effect aspects are present; all three [time] sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine time fields carry ER-derived content.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information (Practical Considerations, Therapeutic Protocol).

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All tiers trace to the ER Expected Benefits section (l.157-239).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four benefit variables are present (l.540, 543, 550, 558).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is a bare benefit label; magnitudes, mechanisms and evidence discussion are stripped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content carried over.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER’s High tier carries no benefit, and [benefits_high] is correctly set to display:none (l.540) rather than filled with empty-state text.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All tiers trace to the ER Potential Risks & Side Effects section (l.265-325).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four risk variables are present (l.621, 627, 633, 639).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is a bare risk label; mechanisms, magnitudes and Conflicted flags are stripped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content carried over.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers (high, medium, low, speculative) carry items.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	All thirteen rows trace to the ER Monitoring Protocol & Defining Success table (l.490-504).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All thirteen ER biomarkers are present: fasting insulin, HOMA-IR, fasting glucose, HbA1c, IGF-1, IGFBP-3, hs-CRP, interleukin-6, triglycerides, ApoB, eGFR and creatinine, ALT and AST, complete blood count.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	l.815-819 carries the full ER cadence: baseline within 4 weeks, daily fasting glucose plus metabolic panel at 2 weeks, full panel at 12 weeks, then every 6 months, with cancer screening unchanged (ER l.486-488).

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items trace to the ER qualitative marker list at l.508-513.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers are present: cognitive clarity and working memory, sleep quality and duration, energy and exercise capacity, body composition by feel and fit of clothing, recovery from training sessions, injection site condition.

Issues 06/08/2026 03:48

Pass rate 100.00%. No issues found.

Issues 06/08/2026 03:41

1. 8.5 — Retinopathy staging qualifier dropped: The last contraindication (QRS line 583) reads “Active proliferative disorder, e.g. untreated diabetic retinopathy”, dropping the clinical-staging qualifier “proliferative” that the ER carries at line 372 (“untreated proliferative diabetic retinopathy”), which broadens the gate beyond what the ER states.

Fixes 06/08/2026 03:41

1. 8.5 — Retinopathy staging qualifier restored: Changed the last contraindication from “untreated diabetic retinopathy” to “untreated proliferative diabetic retinopathy”, matching the ER’s clinical staging at line 372.

Issues 06/08/2026 03:30

1. 4.5 — QRS overflows one A4 page: At the template’s print geometry the sheet renders to roughly 1.9 A4 pages; the Monitoring table (5 of 13 rows wrapping to two lines), the three-line Contraindication and Key Interaction items, the four-line Low benefit line, the two-line Medium/Low/Speculative risk lines and the three-line Protocol sub-cells all carry more text than their per-section budget allows.

Fixes 06/08/2026 03:30

1. 4.5 — Monitoring table reduced to single-line rows: Shortened the target and why cells for HbA1c, IGF-1, IGFBP-3, Interleukin-6, ApoB, ALT/AST and complete blood count (e.g. “Mid-range for age/sex, not lowest quartile” → “Age/sex mid-range” with the quartile caveat moved into the why cell), eliminating all five two-line rows.
2. 4.5 — Risk tiers condensed to one line each: Rewrote the Medium, Low and Speculative risk lines (e.g. “Amplification of senescent cell inflammatory output; perturbation of the IGFBP-3 carrier system; injection-related local and systemic reactions” → “Senescent cell inflammatory amplification; IGFBP-3 carrier perturbation; injection-related reactions”), cutting the card from seven rendered lines to four.
3. 4.5 — Contraindication items shortened: Compressed the malignancy, chemotherapy, pregnancy, paediatric, renal and proliferative-disorder items while retaining the five-year window, the BRCA1/2 and Lynch syndromes and the eGFR < 30 mL/min/1.73 m² threshold, cutting the column from fourteen rendered lines to nine.
4. 4.5 — Key Interaction drug lists trimmed: Shortened the supplement, insulin, mitochondrial-peptide and senolytic example lists to their leading agents, as permitted by 9.5, cutting the column from fourteen rendered lines to twelve.
5. 4.5 — Benefits Low tier condensed: Rewrote the eight Low-tier descriptors more tightly (“prevention of age-related myocardial fibrosis … restraint of plaque progression” → “prevention of myocardial fibrosis … plaque restraint”), taking the line from four rendered lines to three.
6. 4.5 — Protocol and Time-to-effect sub-cells shortened: Trimmed all six sub-cells (e.g. “No approved product, prescribing information, dose, route, frequency or duration in humans.” → “No approved product, dose, route, frequency or duration in humans.”), taking both grid rows from three rendered lines to two.
7. 4.5 — At-A-Glance and Qualitative items tightened: Reduced At-A-Glance from 60 to 59 words to bring it onto four rendered lines, and shortened the cognitive-clarity and injection-site items to one line each.

Issues 06/08/2026 03:22

1. 2.6 / 2.9 — Imperative addressed to reader: marker_13_target (QRS line 814) reads “Reference range; watch lymphocytes”; the imperative “watch” instructs the reader, where the ER states it declaratively as “Within reference range, with attention to lymphocyte count” (ER line 504).

Fixes 06/08/2026 03:22

1. 2.6 / 2.9 — Imperative addressed to reader: Changed marker_13_target from “Reference range; watch lymphocytes” to “Reference range; attention to lymphocyte count”, matching the ER’s declarative phrasing.

Issues 06/08/2026 03:13

1. 1.1 / 1.3 / 7.3 — At-a-glance overstates absence of human exposure: at_a_glance (line 437) states “No person has ever been given it”, but the ER restricts that claim to registered trials (“never been given to a person in a registered trial”, ER line 41) and elsewhere documents actual gray-market human use (ER lines 400, 445, 464), so the QRS strengthens the ER claim beyond what the source supports.

Fixes 06/08/2026 03:13

1. 1.1 / 1.3 / 7.3 — At-a-glance human-exposure claim scoped: Replaced “No person has ever been given it” with “No registered trial has ever given it to a person”, matching the ER’s own scoping of the claim to registered trials. Dropped “short” and “large” elsewhere in the sentence so the passage stays within the 60-word limit of item 7.2.

Issues 06/08/2026 03:05

1. 4.5 — Sheet overruns one A4 page: Composed at the print stylesheet’s A4 geometry the sheet measures roughly 1,700 pt against a 774 pt budget (~2.2 pages), driven mainly by the 13-row Monitoring table (lines 660–859, ~460 pt) and the Qualitative Assessment card (lines 863–904, ~215 pt).
2. 2.8 — ER sentences copied, not compacted: Qualitative Assessment items (lines 866–902), several Monitoring “Why” cells (lines 712, 771, 844) and the cadence paragraph (line 854) carry full ER sentences verbatim rather than compact phrases.
3. 9.4 — Mechanistic rationale in caution item: Line 617 reads “Low-dose aspirin (theoretical competition at the FPR2 receptor)”; the parenthetical is a mechanistic rationale, which 9.4 forbids and 9.5 does not license.

Fixes 06/08/2026 03:05

1. 9.4 — Mechanistic rationale stripped from aspirin item: Changed the last Key Interactions entry from “Low-dose aspirin (theoretical competition at the FPR2 receptor)” to plain “Low-dose aspirin”.
2. 4.5 / 2.8 — Monitoring table condensed: Rewrote nine “Why” cells and three “Target” cells as compact phrases (e.g. marker_13_why from “Humanin protects lymphocytes from cytotoxic injury in animals, making this the most relevant hematological readout” to “Lymphocytes are protected from cytotoxic injury in animals”; marker_6_target from “Within the age-adjusted reference range, interpreted as a ratio to IGF-1” to “Age-adjusted range; ratio to IGF-1”).
3. 4.5 / 2.8 — Monitoring cadence tightened: Reduced the cadence paragraph from three long sentences to “Baseline within 4 weeks before use. Fasting glucose daily and a metabolic panel at 2 weeks; full panel at 12 weeks; then every 6 months. Age-appropriate cancer screening continues on its normal schedule.”
4. 4.5 / 2.8 — Protocol and Time-to-Effect subs compacted: Shortened all six action_#_sub / time_#_sub cells, dropping redundant ER clauses (e.g. time_2_sub lost “body weight differences emerged over months”, time_1_sub reduced to “No perceptible acute effect is reported, so there is no early feedback signal”).
5. 4.5 — Decision gates trimmed: Shortened two Contraindications (“Current or imminent curative-intent chemotherapy or radiotherapy…”) and two Key Interactions (“Growth hormone and secretagogues…”, “Other mitochondrial peptides…”) while keeping every threshold, time window and example drug list intact.
6. 4.5 / 2.8 — Qualitative Assessment items compacted: Reduced all six entries to their ER bold label plus a short clause (e.g. item 1 from “the domain with the strongest preclinical rationale. Best tracked with a repeatable timed task rather than impression.” to “strongest preclinical rationale; tracked with a repeatable timed task.”).
7. 4.5 — Benefits and Risks tiers tightened: Removed redundant repetitions of “protection of” / “prevention of” from benefits_low and shortened risks_speculative to “Immunogenicity and anti-peptide antibodies; chronic gp130 and STAT3 activation; suppression of beneficial apoptosis and mitophagy”, saving a rendered line in each card.